Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2021

11.03.2021 | Hepatobiliary Tumors

Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma

verfasst von: Kota Sahara, MD, Diamantis I. Tsilimigras, MD, Junya Toyoda, MD, Kentaro Miyake, MD, PhD, Cecilia G. Ethun, MD, Shishir K. Maithel, MD, Daniel E. Abbott, MD, George A. Poultsides, MD, Ioannis Hatzaras, MD, Ryan C. Fields, MD, Matthew Weiss, MD, Charles Scoggins, MD, Chelsea A. Isom, MD, Kamran Idrees, MD, Perry Shen, MD, Yasuhiro Yabushita, MD, PhD, Ryusei Matsuyama, MD, PhD, Itaru Endo, MD, PhD, Timothy M. Pawlik, MD, MPH, MTS, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Although multidisciplinary treatments including the use of adjuvant therapy (AT) have been adopted for biliary tract cancers, patients with distal cholangiocarcinoma (DCC) can still experience recurrence. We sought to characterize the incidence and predictors of early recurrence (ER) that occurred within 12 months following surgery for DCC.

Patients and Methods

Patients who underwent resection for DCC between 2000 and 2015 were identified from the US multi-institutional database. Cox regression analysis was used to identify clinicopathological factors to develop an ER risk score, and the predictive model was validated in an external dataset.

Results

Among 245 patients included in the analysis, 67 patients (27.3%) developed ER. No difference was noted in ER rates between patients who did and did not receive AT (28.7% vs. 25.0%, p = 0.55). Multivariable analysis revealed that neutrophil-to-lymphocyte ratio (NLR), peak total bilirubin (T-Bil), major vascular resection (MVR), lymphovascular invasion, and R1 surgical margin status were associated with a higher ER risk. A DIstal Cholangiocarcinoma Early Recurrence Score was developed according to each factor available prior to surgery [NLR > 9.0 (2 points); peak T-bil > 1.5 mg/dL (1 points); MVR (2 points)]. Cumulative ER rates incrementally increased among patients who were low (0 points; 10.6%), intermediate (1–2 points; 26.8%), or high (3–5 points; 57.6%) risk (p < 0.001) in the training dataset, as well as in the validation dataset [low (0 points); 3.4%, intermediate (1–2 points); 32.7%, or high risk (3–5 points); 55.6% (p < 0.001)].

Conclusions

Among patients undergoing resection for DCC, 1 in 4 patients experienced an ER. Alternative treatment strategies such as neoadjuvant chemotherapy may be considered especially among individuals deemed to be at high risk for ER.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. ASCO. 2016;36:e194–203.CrossRef Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. ASCO. 2016;36:e194–203.CrossRef
2.
Zurück zum Zitat Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRef Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRef
3.
Zurück zum Zitat Lopez-Aguiar AG, Ethun CG, Pawlik TM, et al. Association of Perioperative transfusion with recurrence and survival after resection of distal cholangiocarcinoma: a 10-institution study from the US extrahepatic biliary malignancy consortium. Ann Surg Oncol. 2019;26(6):1814–23.CrossRef Lopez-Aguiar AG, Ethun CG, Pawlik TM, et al. Association of Perioperative transfusion with recurrence and survival after resection of distal cholangiocarcinoma: a 10-institution study from the US extrahepatic biliary malignancy consortium. Ann Surg Oncol. 2019;26(6):1814–23.CrossRef
4.
Zurück zum Zitat Hatzaras I, George N, Muscarella P, et al. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17(4):991–7.CrossRef Hatzaras I, George N, Muscarella P, et al. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17(4):991–7.CrossRef
5.
Zurück zum Zitat Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and Oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–67.CrossRef Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and Oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–67.CrossRef
6.
Zurück zum Zitat Sahara K, Farooq SA, Tsilimigras DI, et al. Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. Hepatobiliary Surg Nutr. 2020;9(1):13–24.CrossRef Sahara K, Farooq SA, Tsilimigras DI, et al. Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. Hepatobiliary Surg Nutr. 2020;9(1):13–24.CrossRef
7.
Zurück zum Zitat Zhou W, Qian L, Rong Y, et al. Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma. Radiother Oncol. 2020;147:111–7.CrossRef Zhou W, Qian L, Rong Y, et al. Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma. Radiother Oncol. 2020;147:111–7.CrossRef
8.
Zurück zum Zitat Courtin-Tanguy L, Turrini O, Bergeat D, et al. Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenectomy for distal cholangiocarcinoma. HPB. 2018;20(5):405–10.CrossRef Courtin-Tanguy L, Turrini O, Bergeat D, et al. Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenectomy for distal cholangiocarcinoma. HPB. 2018;20(5):405–10.CrossRef
9.
Zurück zum Zitat Komaya K, Ebata T, Shirai K, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104(4):426–33.CrossRef Komaya K, Ebata T, Shirai K, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104(4):426–33.CrossRef
10.
Zurück zum Zitat Nakanishi Y, Okamura K, Tsuchikawa T, et al. Time to Recurrence After surgical resection and survival after recurrence among patients with perihilar and distal cholangiocarcinomas. Ann Surg Oncol. 2020. Nakanishi Y, Okamura K, Tsuchikawa T, et al. Time to Recurrence After surgical resection and survival after recurrence among patients with perihilar and distal cholangiocarcinomas. Ann Surg Oncol. 2020.
11.
Zurück zum Zitat Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019.
12.
Zurück zum Zitat Tsilimigras DI, Sahara K, Wu L, et al. Very Early Recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020. Tsilimigras DI, Sahara K, Wu L, et al. Very Early Recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020.
13.
Zurück zum Zitat Sahara K, Tsilimigras DI, Kikuchi Y, et al. Defining and predicting early recurrence after resection for gallbladder Cancer. Ann Surgical Oncol. 2020. Sahara K, Tsilimigras DI, Kikuchi Y, et al. Defining and predicting early recurrence after resection for gallbladder Cancer. Ann Surgical Oncol. 2020.
14.
Zurück zum Zitat Lee KJ, Carlin JB. Multiple Imputation for missing data: fully conditional specification versus multivariate normal imputation. Am J Epidemiol. 2010;171(5):624–32.CrossRef Lee KJ, Carlin JB. Multiple Imputation for missing data: fully conditional specification versus multivariate normal imputation. Am J Epidemiol. 2010;171(5):624–32.CrossRef
15.
Zurück zum Zitat Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2018. Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2018.
16.
Zurück zum Zitat Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.CrossRef Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.CrossRef
17.
Zurück zum Zitat Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226–30.CrossRef Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226–30.CrossRef
18.
Zurück zum Zitat Tsilimigras DI, Mehta R, Paredes AZ, et al. Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the Milan criteria. Ann Surg. 2020;272(4):574–81.CrossRef Tsilimigras DI, Mehta R, Paredes AZ, et al. Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the Milan criteria. Ann Surg. 2020;272(4):574–81.CrossRef
19.
Zurück zum Zitat Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69(6):1284–93.CrossRef Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69(6):1284–93.CrossRef
20.
Zurück zum Zitat Sahara K, Tsilimigras DI, Pawlik TM. ASO Author Reflections: Validated prediction model of early recurrence after resection for gallbladder cancer: identifying a subset of patients who may be better served with neoadjuvant therapy. An Surg Oncol. 2020. Sahara K, Tsilimigras DI, Pawlik TM. ASO Author Reflections: Validated prediction model of early recurrence after resection for gallbladder cancer: identifying a subset of patients who may be better served with neoadjuvant therapy. An Surg Oncol. 2020.
21.
Zurück zum Zitat Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2018. Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2018.
22.
Zurück zum Zitat Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848–56.CrossRef Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848–56.CrossRef
23.
Zurück zum Zitat Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterol. 2018;154(1):128-139. Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterol. 2018;154(1):128-139.
24.
Zurück zum Zitat Sahara K, Paredes AZ, Tsilimigras DI, et al. Machine learning predicts unpredicted deaths with high accuracy following hepatopancreatic surgery. Hepatobiliary Surg Nutr. 2019. Sahara K, Paredes AZ, Tsilimigras DI, et al. Machine learning predicts unpredicted deaths with high accuracy following hepatopancreatic surgery. Hepatobiliary Surg Nutr. 2019.
25.
Zurück zum Zitat Semenkovich TR, Yan Y, Subramanian M, et al. A clinical nomogram for predicting node-positive disease in esophageal cancer. Ann Surg. 2019. Semenkovich TR, Yan Y, Subramanian M, et al. A clinical nomogram for predicting node-positive disease in esophageal cancer. Ann Surg. 2019.
26.
Zurück zum Zitat Sahara K, Tsilimigras DI, Mehta R, et al. A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: The “metro-ticket” paradigm. J Surg Oncol. 2019;120(2):223–30.PubMed Sahara K, Tsilimigras DI, Mehta R, et al. A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: The “metro-ticket” paradigm. J Surg Oncol. 2019;120(2):223–30.PubMed
27.
Zurück zum Zitat Smith RA, Ghaneh P, Sutton R, et al. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 2008;12(8):1422–8.CrossRef Smith RA, Ghaneh P, Sutton R, et al. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 2008;12(8):1422–8.CrossRef
28.
Zurück zum Zitat Moro A, Mehta R, Sahara K, et al. The impact of preoperative CA19-9 and CEA on outcomes of patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020. Moro A, Mehta R, Sahara K, et al. The impact of preoperative CA19-9 and CEA on outcomes of patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020.
29.
Zurück zum Zitat Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol (EJSO). 2008;34(1):55–60.CrossRef Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol (EJSO). 2008;34(1):55–60.CrossRef
30.
Zurück zum Zitat Tsilimigras DI, Moris D, Mehta R, et al. The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. HPB. 2020. Tsilimigras DI, Moris D, Mehta R, et al. The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. HPB. 2020.
31.
Zurück zum Zitat Tang H, Lu W, Li B, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(22):36857–68.CrossRef Tang H, Lu W, Li B, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(22):36857–68.CrossRef
32.
Zurück zum Zitat Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250(1):141–51.CrossRef Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250(1):141–51.CrossRef
33.
Zurück zum Zitat Zer A, Sung MR, Walia P, et al. Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non–small-cell lung cancer. Clin Lung Cancer. 2018;19(5):426-434.e421.CrossRef Zer A, Sung MR, Walia P, et al. Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non–small-cell lung cancer. Clin Lung Cancer. 2018;19(5):426-434.e421.CrossRef
34.
Zurück zum Zitat Větvička V, Šíma P, Miler I, Bilej M. The immunosuppressive effects of bilirubin. Folia Microbiol. 1991;36(2):112–9.CrossRef Větvička V, Šíma P, Miler I, Bilej M. The immunosuppressive effects of bilirubin. Folia Microbiol. 1991;36(2):112–9.CrossRef
35.
Zurück zum Zitat Farhat MH, Shamseddine AI, Tawil AN, et al. Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index. W J Gastroenterol. 2008;14(20):3224.CrossRef Farhat MH, Shamseddine AI, Tawil AN, et al. Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index. W J Gastroenterol. 2008;14(20):3224.CrossRef
36.
Zurück zum Zitat Tempero MA, Behrman S, Ben-Josef E, et al. Pancreatic adenocarcinoma: clinical practice guidelines in oncology. JNCCN. 2005;3(5):598–626.PubMed Tempero MA, Behrman S, Ben-Josef E, et al. Pancreatic adenocarcinoma: clinical practice guidelines in oncology. JNCCN. 2005;3(5):598–626.PubMed
37.
Zurück zum Zitat Katz MHG, Pisters PWT, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46.CrossRef Katz MHG, Pisters PWT, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46.CrossRef
38.
Zurück zum Zitat Matsuyama R, Morioka D, Mori R, et al. Our rationale of initiating neoadjuvant chemotherapy for hilar cholangiocarcinoma: a proposal of criteria for “borderline resectable” in the field of surgery for hilar cholangiocarcinoma. World J Surg. 2018. Matsuyama R, Morioka D, Mori R, et al. Our rationale of initiating neoadjuvant chemotherapy for hilar cholangiocarcinoma: a proposal of criteria for “borderline resectable” in the field of surgery for hilar cholangiocarcinoma. World J Surg. 2018.
39.
Zurück zum Zitat Chaudhari VA, Ostwal V, Patkar S, et al. Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications. HPB. 2018;20(9):841–7.CrossRef Chaudhari VA, Ostwal V, Patkar S, et al. Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications. HPB. 2018;20(9):841–7.CrossRef
40.
Zurück zum Zitat Beane JD, Borrebach JD, Zureikat AH, et al. Optimal pancreatic surgery: are we making progress in North America? Ann Surg. 2019. Beane JD, Borrebach JD, Zureikat AH, et al. Optimal pancreatic surgery: are we making progress in North America? Ann Surg. 2019.
41.
Zurück zum Zitat Mierke F, Hempel S, Distler M, et al. Impact of portal vein involvement from pancreatic cancer on metastatic pattern after surgical resection. Ann Surg Oncol. 2016;23(5):730–6.CrossRef Mierke F, Hempel S, Distler M, et al. Impact of portal vein involvement from pancreatic cancer on metastatic pattern after surgical resection. Ann Surg Oncol. 2016;23(5):730–6.CrossRef
43.
Zurück zum Zitat Yadav S, Xie H, Bin-Riaz I, et al. Neoadjuvant versus adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019;45(8):1432–8.CrossRef Yadav S, Xie H, Bin-Riaz I, et al. Neoadjuvant versus adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019;45(8):1432–8.CrossRef
44.
Zurück zum Zitat Goetze TO, Bechstein WO, Bankstahl US, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/ CALGP/ ACO- GAIN-trial –. BMC Cancer. 2020;20(1):122.CrossRef Goetze TO, Bechstein WO, Bankstahl US, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/ CALGP/ ACO- GAIN-trial –. BMC Cancer. 2020;20(1):122.CrossRef
45.
Zurück zum Zitat Okamura Y, Sugiura T, Ito T, et al. Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma. Br J Surg. 2016;103(7):891–8.CrossRef Okamura Y, Sugiura T, Ito T, et al. Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma. Br J Surg. 2016;103(7):891–8.CrossRef
Metadaten
Titel
Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma
verfasst von
Kota Sahara, MD
Diamantis I. Tsilimigras, MD
Junya Toyoda, MD
Kentaro Miyake, MD, PhD
Cecilia G. Ethun, MD
Shishir K. Maithel, MD
Daniel E. Abbott, MD
George A. Poultsides, MD
Ioannis Hatzaras, MD
Ryan C. Fields, MD
Matthew Weiss, MD
Charles Scoggins, MD
Chelsea A. Isom, MD
Kamran Idrees, MD
Perry Shen, MD
Yasuhiro Yabushita, MD, PhD
Ryusei Matsuyama, MD, PhD
Itaru Endo, MD, PhD
Timothy M. Pawlik, MD, MPH, MTS, PhD, FACS
Publikationsdatum
11.03.2021
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-09811-4

Weitere Artikel der Ausgabe 8/2021

Annals of Surgical Oncology 8/2021 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.